Adiponectin and protection against type 2 diabetes mellitus.

By J. Spranger, A. Kroke, M. Möhlig, M. Bergmann, Michael Ristow, H. Boeing, A. Pfeiffer. The Lancet, 2003

1,152 citations recorded by the source corpus.

Subfields: Epidemiology, Immunology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/2e29f98032ad4abc485d97c2c16516d29c3c1ec2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. André Tchernof
2. F. B. Hu
3. J. Despres
4. G. Hotamisligil
5. M. Blüher
6. Michael Ristow
7. N. Rifai
8. P. Ridker

In Immunology

1. Frank O. Nestle
2. J. Krueger
3. G. Hotamisligil

In Pharmacology

1. André Tchernof
2. J. Despres
3. M. Blüher

Citations in the corpus

• Adiponectin: action, regulation and association to insulin sensitivity (2005, background): “obesity reviews 6 , 13–21 Adiponectin levels are reduced in patients with cardiovascular disease (26) and in diabetics (27) and from epidemiological studies low levels of adiponectin are found to be a predictor of the later development of type 2 diabetes (28,29) and myocardial infarction (30,31).”
• Plasma adiponectin levels and risk of myocardial infarction in men. (2004, background): “Furthermore, this type of nonlinear relationship is consistent with other reports on adiponectin and risk of CHD and type 2 diabetes.(13,43) A single assessment of adiponectin may be susceptible to short-termvariation,whichwouldbias the results toward the null.”
• Antioxidants prevent health-promoting effects of physical exercise in humans (2009, background): “Plasma concentrations of the adipocyte-derived secretory protein adiponectin have been shown to be positively correlated with insulin sensitivity in humans and inversely correlated with type 2 diabetes risk (19).”
• Relationship between adipocyte size and adipokine expression and secretion. (2007, background): “Low adiponectin was shown to be predictive for the development of type 2 diabetes (61).”
• Adiponectin Regulation and Function (2018, neutral): “These and additional studies in which adiponectin or HMW/LMW levels were reduced (11, 94, 110, 158, 171, 191, 241, 308) or increased (45, 230, 351, 389, 400) clearly demonstrate that adiponectin promotes insulin sensitivity and decreases insulin resistance (271).”
• Adiponectin: more than just another fat cell hormone? (2003, background): “Conversely, increased baseline concentrations of adiponectin may be associated with a reduced risk of developing type 2 diabetes (66).”
• Pathophysiology of human visceral obesity: an update. (2013, background): “It appears clear, however, that low adiponectinemia predicts an increased risk of type 2 diabetes (322, 529).”